title: GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.
abstract: Mood disorder patients that are on long-term atypical antipsychotics treatment frequently experience metabolic dysfunctions. In addition to this, accumulating evidences points to increased risk of structural abnormalities, brain volume changes, altered neuroplasticity and behavioral depression with long-term antipsychotics use. However, there is paucity of preclinical evidences for long-term antipsychotic associated depression-like behavior. The objectives of the present study were: (1) to evaluate influence of long-term antipsychotic (olanzapine) treatment on rat behavior in forced swim test (FST) as a model for depression and; (2) to examine impact of glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide - an antidiabetic medication for type II diabetes, on long-term olanzapine associated metabolic and behavioral changes in rats. Daily olanzapine treatment (0.5 mg/kg; p.o.) for 8-9 weeks significantly increased body weights, food and water intake, plasma cholesterol and triglycerides and immobility time in FST with parallel reduction in plasma HDL cholesterol levels. These results points to development of metabolic abnormalities and depression-like behavior with long-term olanzapine treatment. Acute liraglutide (50 μg/kg; i.p.) and imipramine (10 mg/kg, i. p.) treatment per se significantly decreased duration of immobility in FST compared to vehicle treated rats. Additionally, 3-week liraglutide treatment (50 μg/kg; i.p., daily) partially reversed metabolic abnormalities and depression-like behavior with long-term olanzapine-treatment in rats. None of these treatment regimens affected locomotor behavior of rats. In summary, add-on GLP-1 receptor agonists promise novel alternatives to counteract long-term antipsychotics associated behavioral and metabolic complications.
authors.affiliation: Department of Pharmacology, S.T.E.S.s Smt. Kashibai Navale College of Pharmacy, Kondhwa (Bk), Pune, MS, 411048, India, Ajay.Kumar.N.Sharma@uth.tmc.edu.
authors.forename: Ajaykumar N
authors.initials: AN
authors.lastname: Sharma
authors.forename: Sagar S
authors.initials: SS
authors.lastname: Ligade
authors.forename: Jay N
authors.initials: JN
authors.lastname: Sharma
authors.forename: Praveen
authors.initials: P
authors.lastname: Shukla
authors.forename: Khalid M
authors.initials: KM
authors.lastname: Elased
authors.forename: James B
authors.initials: JB
authors.lastname: Lucot
mesh_terms: D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000633:toxicity*; D001569:Benzodiazepines / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D003863:Depression / Q000139:chemically induced* / Q000188:drug therapy*; D004435:Eating / Q000187:drug effects; D005260:Female; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007099:Imipramine / Q000627:therapeutic use; D000069450:Liraglutide / Q000627:therapeutic use*; D008659:Metabolic Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D009043:Motor Activity / Q000187:drug effects; D000077152:Olanzapine; D051381:Rats; D017208:Rats, Wistar; D013550:Swimming / Q000523:psychology; D014280:Triglycerides / Q000097:blood; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
chemical_list: D000929:Antidepressive Agents, Tricyclic; D014150:Antipsychotic Agents; D007004:Hypoglycemic Agents; D014280:Triglycerides; D001569:Benzodiazepines; D000069450:Liraglutide; D002784:Cholesterol; D000077152:Olanzapine; D007099:Imipramine; D000097789:Glucagon-Like Peptide-1 Receptor Agonists